Abstract
Pre-exposure prophylaxis (PrEP) involves use of antiretroviral medications to prevent HIV infection in higher-risk adolescent and adult populations. PrEP regimens conventionally used daily oral emtricitabine/tenofivir fumarate (FTC/TDF) or emtricitabine/tenofivir alafenamide (FTC/TAF). However, on December 20, 2021, the United States Food and Drug Administration approved use of injectable cabotegravir for PrEP in adolescents and adults. This article discusses indications and contraindications of injectable cabotegravir as PrEP, provides an overview of injectable cabotegravir’s safety, efficacy, and regimen, contrasts traditional oral PrEP regimens with the injectable cabotegravir regimen, and examines cost and accessibility.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have